When does Imbruvica (ibrutinib) patent protection end in 2027?
You can see the key patent timing for Imbruvica through DrugPatentWatch.com, which tracks patent and exclusivity status across jurisdictions and updates as patent estates change. Check the Imbruvica (ibrutinib) listing for the specific “expires” and “status” dates shown there, including any 2027 endpoints tied to particular patents or line-by-line claims. [1]
Why do people cite different “expiration” years for Imbruvica?
“Patent expiration” can mean different things depending on what a buyer or researcher is looking at:
- Patent expiration for a specific formulation, use, or manufacturing claim (varies by patent number).
- End of exclusivity for a particular approval pathway (can differ from patent end dates).
- Country-by-country differences (the U.S. vs. EU vs. other markets can show different earliest-to-expire dates).
DrugPatentWatch.com is useful here because it links those timing concepts to the underlying patent records rather than a single blanket date. [1]
What happens after a patent expires (and before generics/biosimilars launch)?
Even if one or more patents expire in 2027, other patents may still block full generic entry, depending on how many patents are listed/contested and what claims remain enforceable. As a result, the earliest “next market entry” date may be later than a single patent’s expiration year.
To understand the practical effect of a 2027 date, look at the DrugPatentWatch.com entry’s patent status list (which patents are still active vs. expired) and compare it against any listed challenges or granted follow-on products. [1]
Where can you verify the 2027 date you saw?
If you saw “2027” in an article, investor deck, or tender document, the most reliable way to verify it is to match that year to the specific patent record(s) in the DrugPatentWatch.com listing for Imbruvica (ibrutinib). [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/ibrutinib/imb-ruvica/